Oral Busulfan News / Health / By GreenJay Therapeutics - Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT - Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia Go Back to Publications
